Sign inJoin waitlistJoin the waitlist

Orwa Aboud

Assistant Professor, Department of Neurology and Neurological Surgery · University of California Davis Health

Credentials: · · · ·

History

University of California Davis Health
Present
University of California Davis Health
Present

Johns Hopkins Hospital
2019–2020
National Institutes of Health
2017–2019
Neurology
University of Arkansas for Medical Sciences
2013–2014
Faculty of Medicine of Damascus University
2003–2007

Research

Loss of angiotensin II receptor expression in dopamine neurons in Parkinson's disease correlates with pathological progression and is accompanied by increases in Nox4- and 8-OH…
Acta Neuropathologica Communications · 2015 · 56 citations
Epidermal Growth Factor Receptor Inhibitors in Glioblastoma: Current Status and Future Possibilities
Review · International Journal of Molecular Sciences · 2024 · Last of 4 authors · Corresponding · 52 citations
Epilepsy: neuroinflammation, neurodegeneration, and APOE genotype
Acta Neuropathologica Communications · 2013 · First of 4 authors · 31 citations

Han Lee
11 papers
John Aboubechara
9 papers · 9 as a resident
Orin Bloch
8 papers
Marta Penas-Prado
7 papers
Ruben Fragoso
7 papers
Brett Theeler
6 papers
HM
Haitham Maraqah
6 papers
Kenneth Aldape
6 papers
Martha Quezado
5 papers
Nina Yu
5 papers · 4 as a resident
Robert Mrak
5 papers
Yin Liu
5 papers

Clinical trials

Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
Principal investigator · Recruiting · Phase 1
University of California, Davis
2025–2027
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2026–2040
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
Site PI · Recruiting · Phase 1
National Cancer Institute (NCI)
2025–2027
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
Site PI · Recruiting · Phase 1, Phase 2
National Cancer Institute (NCI)
2023–2027